VEGF 165 (AA 27-191) (Active) Protein

Produktnummer ABIN7275824

Recombinant VEGF 165-Protein exprimiert in HEK-293 Cells.

Kurzübersicht für VEGF 165 (AA 27-191) (Active) Protein (ABIN7275824)

Target: VEGF 165

Protein-Typ: Recombinant

Biologische Aktivität: Active

Spezies: Human

Quelle: HEK-293 Cells

Reinheit: > 95 % as determined by Bis-Tris PAGE,> 95 % as determined by HPLC

Produktdetails

Proteineigenschaft: AA 27-191

Verwendungszweck: Human VEGF165 Protein

Sequenz: Ala27-Arg191

Produktmerkmale: Recombinant Human VEGF165 Protein is expressed from HEK293 without tag.It contains Ala27-Arg191.

Sterilität: 0.22 μm filtered

Endotoxin-Niveau: Less than 0.05 EU per μg by the LAL method.

Biological Activity Comment: Immobilized Human VEGF165 at 1ug/ml (100ul/well) on the plate. Dose response curve for Biotinylated Human VEGFR1, His Tag with the EC50 of 46.4ng/ml determined by ELISA.,Immobilized Human VEGF165, No Tag at 5ug/ml (100ul/well) on the plate. Dose response curve for Human VEGF R2, HisTag (Cat. VGF-HM1R2) with the EC50 of 0.35ug/ml determined by ELISA.,Immobilized Human VEGF165, No Tag at 1ug/ml (100ul/well) on the plate. Dose response curve for Anti-VEGF165 Antibody, hFc Tag with the EC50 of 2.7ng/ml determined by ELISA.,Human VEGF165 on Bis-Tris PAGE under reduced condition and Non reduced (N) condition. The purity is greater than 95%.,Measured by a reporter gene assay using HEK293T-KDR-NFAT Cell line. The ED50-for this effect is < 10 ng/mL (QC Test).,Serial dilutions of Anti-VEGF165 Antibody were added into Human VEGF165, No Tag: Biotinylated Human VEGF R2, His Avi Tag binding reactioins. The half maximal inhibitiory concentration (IC50) is 0.30ug/ml.,The purity of Human VEGF165 is greater than 95% as determined by SEC-HPLC.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Dissolve the lyophilized protein in distilled water. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1 mg/mL for 500 μg or 1 mg lyophilized powder. Do not mix by vortex or vigorous shaking.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3 months after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Haltbarkeit: 12 months

Antigendetails

Target: VEGF 165

Andere Bezeichnung: VEGF165

Hintergrund: Human papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis.

Molekulargewicht: 19.2 kDa. Due to glycosylation, the protein migrates to 20-30 kDa based on Bis-Tris PAGE result.

UniProt: P15692